DELCOR Family Office backs Melbourne Based Drug Development Company AdAlta (ASX:1AD)

June 13, 2017

DELCOR Family Office recently backed a AUD$10m funding round of ASX listed AdAlta Limited (ASX:1AD).  AdAlta is a drug discovery and development company focused on using its powerful technology platform to generate a promising new class of i-bodies, for treating a wide range of human diseases.


AdAlta is a drug discovery and development company focused on using its proprietary technology platform to generate a new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases.

The Initial focus is on treating fibrosis with AdAlta lead fibrosis drug candidate AD-114. This drug is fully funded for phase 1 development of the lead fibrosis drug and i-body.

AdAlta’s new technology platform produces unique proteins known as i-bodies, that mimic the shape of shark antibody binding domain and engineers their key stability features into a human protein, for therapeutic intervention in disease. The single domain antigen binding region of shark antibodies is extremely stable and has a long binding loop not present in either human or next generation antibodies.

1AD share price since listing in August 2016:

Investor Presentation by Managing Director & CEO, Sam Cobb AdAlta InvestorPresentation